WT
Elite in Leiomyosarcoma

Dr. William D. Tap

Memorial Sloan Kettering Cancer Center
New York, NY
Elite
 in Leiomyosarcoma
Specialties:Hematology Oncology
Experience:23 Years
Clinical Trials:Currently Recruiting for 1 Trial
Accepts:New PatientsMedicare
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. William D. Tap's experience treating your condition:
About Dr. William D. Tap

William Tap is a Hematologist Oncology expert in New York, New York. Tap has been practicing medicine for over 23 years and is rated as an Elite expert by MediFind in the treatment of Leiomyosarcoma. He is also highly rated in 35 other conditions, according to our data. His top areas of expertise are Adult Soft Tissue Sarcoma, Angiosarcoma, Synovial Sarcoma, Tissue Biopsy, and Liver Embolization. He is licensed to treat patients in California and New York. Tap is currently accepting new patients.

His clinical research consists of co-authoring 176 peer reviewed articles and participating in 16 clinical trials in the past 15 years. In particular, he has co-authored 13 articles and participated in 6 clinical trials in the study of Leiomyosarcoma.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. William D. Tap it is best to call his office and ask if your insurance is accepted.

Accepts Medicare
Locations
1275 York Ave, New York, NY 10065
Background & Education
Graduate Institution
Jefferson Medical College Of Thomas Jefferson University, 2000
Specialties
Hematology Oncology
Licenses
Internal Medicine in CA
Hospital Affiliations
Memorial Sloan Kettering Cancer Center
Shore Medical Center
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials
Phase II Study of Niraparib in Soft Tissue Sarcoma Patients With Altered DNA Damage Repair
Enrollment Status: Recruiting
Publish Date: September 08, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Randomized Phase 3, Multicenter, Open-Label Study Comparing TH-302 in Combination With Doxorubicin vs. Doxorubicin Alone in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
Enrollment Status: Completed
Publish Date: June 02, 2016
Intervention Type: Drug
Study Phase: Phase 3
An Open-Label, Multicenter, Phase 1a/1b Study of Olaratumab (LY3012207) Plus Pembrolizumab (MK3475) in Patients With Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma (STS) Who Have Failed Standard Treatments
Enrollment Status: Active, not recruiting
Publish Date: July 20, 2022
Intervention Type: Drug
Study Drugs: OlaratumabPembrolizumab
Study Phase: Phase 1
A Phase 2 Study of Temsirolimus (CCI-779, NSC 683864) and IGF-1 Receptor Antibody Cixutumumab (IMC-A12, NSC 742460) in Patients With Metastatic Sarcomas
Enrollment Status: Completed
Publish Date: July 30, 2015
Intervention Type: Drug, Other, Biological
Study Phase: Phase 2
A Phase IB/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
Enrollment Status: Terminated
Publish Date: January 11, 2018
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Phase II Trial Of Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes
Enrollment Status: Completed
Publish Date: January 25, 2016
Intervention Type: Drug
Study Phase: Phase 2
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
Enrollment Status: Completed
Publish Date: October 06, 2022
Intervention Type: Drug
Study Drugs: AvapritinibRegorafenib
Study Phase: Phase 3
A Randomized, Multicenter, Double-Blind, Phase II Trial of a KLH Conjugated Trivalent Ganglioside Vaccine Containing GM2, GD2 Lactone, and GD3 Lactone With the Immunological Adjuvant OPT-821 Versus OPT-821 Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
Enrollment Status: Completed
Publish Date: April 12, 2017
Intervention Type: Biological
Study Phase: Phase 2
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Determine the Efficacy and Safety of CMB305 in Unresectable Locally-advanced or Metastatic NY-ESO-1+ Synovial Sarcoma Participants Following First Line Systemic Anti-cancer Therapy (V943-003, IMDZ-04-1702)
Enrollment Status: Terminated
Publish Date: April 16, 2020
Intervention Type: Biological, Other
Study Phase: Phase 3
A Phase Ib/II Study of BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Enrollment Status: Completed
Publish Date: March 30, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1b Study of LY3039478 in Combination With Other Anticancer Agents in Patients With Advanced or Metastatic Solid Tumors
Enrollment Status: Completed
Publish Date: August 17, 2020
Intervention Type: Drug
Study Phase: Phase 1
Phase II Trial of Sorafenib and Dacarbazine in Soft Tissue Sarcoma
Enrollment Status: Completed
Publish Date: November 20, 2015
Intervention Type: Drug
Study Phase: Phase 2
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) VS. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Enrollment Status: Terminated
Publish Date: August 23, 2022
Intervention Type: Drug
Study Drugs: PazopanibPazopanib HydrochlorideSapanisertib
Study Phase: Phase 1/Phase 2
A Phase II Study of Sorafenib and Ifosfamide as a Treatment for Patients With Sarcoma
Enrollment Status: Terminated
Publish Date: August 10, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 13 Less Clinical Trials -
176 Total Publications
Histopathologic Grading Is of Prognostic Significance in Primary Angiosarcoma of Breast: Proposal of a Simplified 2-tier Grading System.
Journal: The American journal of surgical pathology
Published: November 15, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
MK
Dr. Mary L. Keohan
Hematology Oncology | Oncology
Elite
Highly rated in
35
conditions
Hematology Oncology
Oncology

Memorial Sloan Kettering Cancer Center

430 E 67th St, 
New York, NY 
 0.1 mi

Mary Keohan is a Hematologist Oncology specialist and an Oncologist in New York, New York. Keohan has been practicing medicine for over 32 years and is rated as an Elite expert by MediFind in the treatment of Leiomyosarcoma. She is also highly rated in 35 other conditions, according to our data. Her top areas of expertise are Adult Soft Tissue Sarcoma, Gastrointestinal Stromal Tumor, Leiomyosarcoma, Synovial Sarcoma, and Liver Embolization. She is licensed to treat patients in New York. Keohan is currently accepting new patients.

SM
Dr. Sujana Movva
Oncology | Hematology Oncology | Hematology
Elite
Highly rated in
25
conditions
Oncology
Hematology Oncology
Hematology

Memorial Sloan Kettering Cancer Center

1275 York Ave, 
New York, NY 

Sujana Movva is an Oncologist and a Hematologist Oncology expert in New York, New York. Movva has been practicing medicine for over 20 years and is rated as an Elite expert by MediFind in the treatment of Leiomyosarcoma. She is also highly rated in 25 other conditions, according to our data. Her top areas of expertise are Adult Soft Tissue Sarcoma, Leiomyosarcoma, Epithelioid Sarcoma, and Undifferentiated Pleomorphic Sarcoma. She is licensed to treat patients in Georgia, Michigan, and Pennsylvania. Movva is currently accepting new patients.

MD
Dr. Mark A. Dickson
Hematology Oncology
Distinguished
Highly rated in
33
conditions
Hematology Oncology

Memorial Sloan Kettering Cancer Center Physicians

353 E 68th St, 
New York, NY 
 0.2 mi

Mark Dickson is a Hematologist Oncology expert in New York, New York. Dickson has been practicing medicine for over 20 years and is rated as a Distinguished expert by MediFind in the treatment of Leiomyosarcoma. He is also highly rated in 33 other conditions, according to our data. His top areas of expertise are Bone Tumor, Liposarcoma, Adult Soft Tissue Sarcoma, Epithelioid Sarcoma, and Endoscopy. He is licensed to treat patients in New York. Dickson is currently accepting new patients.